Actuate to present promising data on elraglusib in advanced salivary gland carcinoma at the aacr annual meeting 2025

Chicago and fort worth, texas, april 17, 2025 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (“actuate” or the “company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (gsk-3Β), today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the american association for cancer research (aacr) annual meeting 2025 taking place from april 25th – 30th at mccormick place convention center, chicago, il. the abstracts will be published in the online proceedings of the aacr.
ACTU Ratings Summary
ACTU Quant Ranking